Acquisition by Rock Edwin of 190000 shares of GlycoMimetics at 0.2532 subject to Rule 16b-3
| GLYC Stock | USD 0.29 0.01 3.57% |
About 55% of GlycoMimetics' shareholders are presently thinking to get in. The analysis of the overall investor sentiment regarding GlycoMimetics suggests that some traders are interested. The current market sentiment, together with GlycoMimetics' historical and current headlines, can help investors time the market. In addition, many technical investors use GlycoMimetics stock news signals to limit their universe of possible portfolio assets.
GlycoMimetics |
Filed transaction by GlycoMimetics Officer: Chief Medical Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
GlycoMimetics Fundamental Analysis
We analyze GlycoMimetics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlycoMimetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlycoMimetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Employees
Number Of Employees Comparative Analysis
GlycoMimetics is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
GlycoMimetics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with GlycoMimetics stock to make a market-neutral strategy. Peer analysis of GlycoMimetics could also be used in its relative valuation, which is a method of valuing GlycoMimetics by comparing valuation metrics with similar companies.
Peers
GlycoMimetics Related Equities
| ASMB | Assembly Biosciences | 6.63 | ||||
| CUE | Cue Biopharma | 4.93 | ||||
| ANTX | AN2 Therapeutics | 4.67 | ||||
| BCAB | Bioatla | 4.55 | ||||
| TRVI | Trevi Therapeutics | 1.50 | ||||
| SPRO | Spero Therapeutics | 1.23 | ||||
| IVA | Inventiva | 1.21 | ||||
| MLYS | Mineralys Therapeutics, | 0.39 | ||||
| FHTX | Foghorn Therapeutics | 0.49 | ||||
| ACHL | Achilles Therapeutics | 0.72 | ||||
| DYN | Dyne Therapeutics | 1.00 | ||||
| TIL | Instil Bio | 3.52 |
Complementary Tools for GlycoMimetics Stock analysis
When running GlycoMimetics' price analysis, check to measure GlycoMimetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlycoMimetics is operating at the current time. Most of GlycoMimetics' value examination focuses on studying past and present price action to predict the probability of GlycoMimetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlycoMimetics' price. Additionally, you may evaluate how the addition of GlycoMimetics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |